Literature DB >> 18205225

Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro.

Upal Roy1, Scott A Simpson, Debasis Mondal, Sandra Eloby-Childress, Elsa L Winsor, Mark A Beilke.   

Abstract

Co-infections with HIV-1 and the human T leukemia virus types 1 and 2 (HTLV-1, HTLV-2) occur frequently, particularly in large metropolitan areas where injection drug use is a shared mode of transmission. Recent evidence suggests that HIV-HTLV co-infections are associated with upregulated HTLV-1/2 virus expression and disease. An in vitro model of HIV-1 and HTLV-1/2 co-infection was utilized to determine if cell free HIV-1 virions or recombinant HIV-1 Tat protein (200-1,000 ng/ml) upregulated HTLV-1/2 expression and infectivity. Exposure to HIV-1 increased the number of HTLV-1 antigen expressing cells, from 6% at baseline to 12% at 24 hr, and 20% at 120 hr (P < 0.05) post-exposure. A similar, although less robust response was observed in HTLV-2 infected cells. HIV-1 co-localized almost exclusively with HTLV-1/2 positive cells. Exposure to HIV-1 Tat protein (1,000 ng/ml) increased HTLV-1 p19 expression almost twofold by 48 hr, and cells co-stimulated with 10 nM phorbol myristate acetate (PMA) showed almost a fourfold increase over baseline. It is concluded that HIV-1 augments HTLV-1/2 infectivity in vitro. The findings also suggest a role for the HIV-1 Tat protein and PMA-inducible cellular factors, in HIV-1 induced HTLV-1/2 antigen expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205225      PMCID: PMC2769251          DOI: 10.1002/jmv.21089

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  34 in total

1.  In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs.

Authors:  A Machuca; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2000-06-01       Impact factor: 3.731

Review 2.  Regulation of HIV-1 transcription by protein phosphatase 1.

Authors:  Sergei Nekhai; Marina Jerebtsova; Angela Jackson; William Southerland
Journal:  Curr HIV Res       Date:  2007-01       Impact factor: 1.581

3.  High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland.

Authors:  J F Egan; B O'Leary; M J Lewis; F Mulcahy; N Sheehy; H Hasegawa; F Fitzpatrick; J J O'Connor; J O'Riordan; W W Hall
Journal:  AIDS Res Hum Retroviruses       Date:  1999-05-20       Impact factor: 2.205

4.  Effect of HIV type 1 Tat protein on butyric acid-induced differentiation in a hematopoietic progenitor cell line.

Authors:  D Mondal; K C Agrawal
Journal:  AIDS Res Hum Retroviruses       Date:  1996-11-01       Impact factor: 2.205

5.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Presence of human immunodeficiency virus (HIV) and T-lymphotropic virus type I and II (HTLV-I/II) in a haemophiliac population in Belo Horizonte, Brazil, and correlation with additional serological results.

Authors:  A B Carneiro-Proietti; M V Lima-Martins; V M Passos; R A Carmo; S R Pinheiro; P R Rocha; F A Proietti; P C Ferreira; V G Rocha
Journal:  Haemophilia       Date:  1998-01       Impact factor: 4.287

7.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2.

Authors:  Mark A Beilke; Katherine P Theall; Megan O'Brien; John L Clayton; Stephanie M Benjamin; Elsa L Winsor; Patricia J Kissinger
Journal:  Clin Infect Dis       Date:  2004-06-25       Impact factor: 9.079

Review 9.  Human retroviruses after 20 years: a perspective from the past and prospects for their future control.

Authors:  Robert C Gallo
Journal:  Immunol Rev       Date:  2002-07       Impact factor: 12.988

Review 10.  Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders.

Authors:  Ezra Aksoy; Michel Goldman; Fabienne Willems
Journal:  Int J Biochem Cell Biol       Date:  2004-02       Impact factor: 5.085

View more
  1 in total

1.  Assessment of HTLV-I proviral load, HIV viral load and CD4 T cell count in infected subjects; with an emphasis on viral replication in co-infection.

Authors:  Hossein Rahimi; Seyyed Abdolrahim Rezaee; Narges Valizade; Rosita Vakili; Houshang Rafatpanah
Journal:  Iran J Basic Med Sci       Date:  2014-01       Impact factor: 2.699

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.